Vascular Innovations Webinars

We’re excited to announce Industry-led webinars, hosted by the SVS Foundation, that will convene leading experts to present the latest evidence, case-based discussions and real-world insights shaping vascular access and endovascular care.

Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies, or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.

Upcoming Webinars

Wednesday, April 29 - 6:00 p.m. CDT | Scientific and Clinical Insights into Acellular Tissue Engineered Vessels, Presented by Humacyte

Join leading experts for an in-depth discussion on the science, clinical outcomes and real-world application of Symvess® Acellular Tissue Engineered Vessel (ATEV), a conduit innovation in vascular surgery in the last four decades specifically for the vascular trauma indication.

Featured Speakers

Laura Niklason, MD, PhD, Founder, President, and CEO, Humacyte

Dr. Niklason will provide an overview of Humacyte and a scientific analysis of the Symvess® Acellular Tissue Engineered Vessel (ATEV^™) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.¹

Todd Rasmussen, MD, Vascular Surgeon

Dr. Rasmussen will review ATEV clinical evidence from completed studies and patient cases, and provide insights into intraoperative ATEV handling techniques.

Interactive Discussion

The program will conclude with a live discussion session to address audience questions hosted by Dr. Niklason and Dr. Rasmussen, giving attendees the opportunity to engage directly with the faculty and explore this innovation in greater depth.

About Symvess® Acellular Tissue Engineered Vessel

The United States FDA approval of the Symvess® Acellular Tissue Engineered Vessel (ATEV) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible represents one of the only conduit innovations in vascular surgery in the last four decades specifically for the vascular trauma indication.¹ Symvess is a bioengineered human vessel that is readily available off-the-shelf and is designed to repopulate with the patient’s own cells over time.¹

Reference

Symvess U.S. Prescribing Information. Durham, NC. Humacyte Global, Inc.

INDICATION: SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

BOXED WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.

Warnings and Precautions: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.

Adverse Reactions: The most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.

Click here to obtain a copy of the Symvess
U.S. Prescribing Information and Boxed Warning
and see above for Important Safety Information

Trademarks are owned by Humacyte Global Inc.
© 2026 Humacyte Global, Inc. All Rights Reserved. US-SYM-000321 3/26

Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.

This webinar is free to attend. After clicking "register now," to complete registration, you’ll need to login to your SVS member account. If you’re not an SVS member, simply create a free account to continue.

Wednesday, May 13 - 6:00 p.m. CDT | Precision. Control. Completion: Elevating Arterial Thrombectomy with Artix, Presented by Stryker

This webinar will provide an overview of the current treatment landscape for arterial thromboembolism, highlighting unmet clinical needs addressed by the Artix thrombectomy system. Attendees will also gain insights into the latest clinical data supporting Artix, along with real-world case examples demonstrating its practical application.

Faculty

Adam Gwozdz, Stryker

Additional Faculty

Anahita Dua, MD
Khanjan 'KJ' Nagarsheth, MD

This webinar is free to attend. After clicking "register now," to complete registration, you’ll need to login to your SVS member account. If you’re not an SVS member, simply create a free account to continue.

Past Webinars

Missed the webinars or want a replay? The full recordings are now available to watch on demand on SVS VascuLEARN.

February 25, 2026 - Evolving Algorithms in Vascular Access Creation, Presented by Laminate Medical

Challenges in AV fistula creation and durability persist despite adherence to traditional creation strategies. This webinar explores how hemodynamic insights and extravascular support are informing a more refined, data-driven algorithm of care.

This webinar will examine how:

Hemodynamic insights are informing better access planning and outcomes
Extravascular support is shaping a more refined, evidence-based approach
Evolving research is translating into practical adoption in real-world care

Learn how extravascular support can lead to improvements in:

Cannulation success
Complication rates
Access durability and long-term management

Designed for vascular surgeons and professionals across the dialysis care continuum, the discussion will bridge research foundations with practical decision-making to support improved outcomes in access creation and long-term maintenance.

Speakers:

Dr. George Blessios
Dr. Ellen Dillavou
Dr. Mohamad Hussain

View the Recording

January 28, 2026 - From PROMISE to Practice: A New Era for CLTI Care, Presented by Inari - now part of Stryker

Up to 10% of patients with chronic limb-threatening ischemia (CLTI) have exhausted all conventional revascularization options and face a devastating risk of major amputation. Transcatheter arterialization of the deep veins (TADV) with the purpose-built LimFlow System is redefining what’s possible for these no-option patients by restoring blood flow to the foot through the venous system.

Following the encouraging limb-salvage and functional outcomes demonstrated in PROMISE I and the pivotal PROMISE II trial, the PROMISE III study takes the next step—prospectively examining both clinical outcomes and the physiologic maturation of the TADV circuit. In this exclusive webinar, investigators unveil the 6-month primary endpoint results from PROMISE III, showcasing real-world hemodynamic evolution, circuit maturation, and wound-healing patterns that deepen our understanding of how LimFlow works and who benefits most.

Join us for an in-depth discussion on how this innovative therapy is expanding treatment possibilities and reshaping the care paradigm for patients with no-option CLTI.

Learning Objectives:

Understand the unmet need in no-option CLTI and where TADV with LimFlow fits in today’s treatment landscape
Gain practical insight into the TADV procedure, including its physiologic rationale, mechanism of action, and key procedural steps
Evaluate the latest clinical evidence supporting LimFlow therapy, with a focused review of PROMISE III 6-month outcomes and their impact on patient selection, limb salvage, and wound healing

Speakers:

Dr. Jocelyn Beach | Dartmouth Health
Dr. Daniel Clair | Vanderbilt University Medical Center
Dr. Adam Gwozdz | Inari/Stryker

View the Recording

November 12, 2025 - End Stage Kidney Disease & Vascular Access: “Innovation & Improved Fistula Outcomes" Presented by Laminate Medical

Program Highlights

Dr. Keith Ozaki will open with a discussion on the hemodynamic and mechanical factors driving fistula failure, their impact on outcomes, and how VasQ’s unique extravascular support mechanism addresses these challenges.
Dr. Ellen Dillavou will review the extensive clinical evidence behind VasQ, including insights from 15 peer-reviewed publications and her personal clinical experience with the device.
Dr. John Lucas will share his real-world perspective, focusing on basilic vein transpositions and how VasQ integration has improved patient outcomes in his ESKD practice.

What to Expect

30-minute presentation with expert-led discussions
15 minutes of Q&A to address your questions
Interactive participant survey

Discover how VasQ is reshaping fistula care and delivering meaningful results for patients with ESKD.

Speakers: Dr. Keith Ozaki, Dr. Ellen Dillavou, Dr. John Lucas

View the Recording

October 29, 2025 - From Data to Decisions: Optimizing Outcomes in PAD & CLI with Eluvia DES Presented by Boston Scientific

This session will highlight the latest clinical evidence on the Eluvia Drug-Eluting Stent (DES), including insights from the SPORTS RCT, Eluvia Pooled Meta-Analysis, and Eluvia TRUE-PTX data. Faculty experts will discuss how these findings reinforce Eluvia’s advantages over alternative modalities—particularly in treating long, challenging lesions.

Through case-based discussions and interactive dialogue, participants will gain practical strategies for integrating DES therapy into real-world practice and comparing its role to DCB and BMS approaches.

Key topics include:

Clinical data reinforcing Eluvia DES effectiveness
Case insights on long, complex lesions
DES vs. DCB/BMS in decision-making
Real-world outcomes: reduced amputations and re-hospitalizations
Impact on patient quality of life and hospital economics

Don’t miss this opportunity to deepen your knowledge and explore how DES therapy can improve outcomes for patients with PAD and CLI.

Speakers: Dr. Anahita Dua, Massachusetts General Hospital, Dr. Sonya Noor, Buffalo General Medical Center, and Dr. Peter Schneider University of California, San Francisco

View the Recording